By Professor Michael John Rogers

Journal articles

Van Wesenbeeck L; Odgren PR; Coxon FP; Frattini A; Moens P; Perdu B; MacKay CA; Van Hul E; Timmermans JP; Vanhoenacker F; Jacobs R; Peruzzi B; Teti A; Helfrich MH; Rogers MJ; Villa A; Van Hul W, 2007, 'Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans', Journal of Clinical Investigation, 117, pp. 919 - 930, http://dx.doi.org/10.1172/JCI30328

Desai B; Rogers MJ; Chellaiah MA, 2007, 'Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells', Molecular Cancer, 6, http://dx.doi.org/10.1186/1476-4598-6-18

Taylor A; Rogers MJ; Tosh D; Coxon FP, 2007, 'A novel method for efficient generation of transfected human osteoclasts', Calcified Tissue International, 80, pp. 132 - 136, http://dx.doi.org/10.1007/s00223-006-0245-6

Roelofs AJ; Thompson K; Gordon S; Rogers MJ; Boyce ; Roodman ; Suva ; Coleman ; Weilbaecher ; Bruland ; Vessella ; Lipton , 2006, 'Molecular mechanisms of action of bisphosphonates: Current status', Clinical Cancer Research, 12, http://dx.doi.org/10.1158/1078-0432.CCR-06-0843

Coxon FP; Thompson K; Rogers MJ, 2006, 'Recent advances in understanding the mechanism of action of bisphosphonates', Current Opinion in Pharmacology, 6, pp. 307 - 312, http://dx.doi.org/10.1016/j.coph.2006.03.005

Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RGG; Oppermann U, 2006, 'The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs', Proceedings of the National Academy of Sciences of the United States of America, 103, pp. 7829 - 7834, http://dx.doi.org/10.1073/pnas.0601643103

Thompson K; Rogers MJ; Coxon FP; Crockett JC, 2006, 'Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis', Molecular Pharmacology, 69, pp. 1624 - 1632, http://dx.doi.org/10.1124/mol.105.020776

Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP, 2006, 'Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases', Journal of Bone and Mineral Research, 21, pp. 684 - 694, http://dx.doi.org/10.1359/jbmr.060118

Thompson K; Rojas-Navea J; Rogers MJ, 2006, 'Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway', Blood, 107, pp. 651 - 654, http://dx.doi.org/10.1182/blood-2005-03-1025

Thompson K; Kikuvi TM; Rogers MJ, 2006, 'Alkylamines prevent osteoclast formation and activity by inhibiting the mevalonate pathway', Bone, 38, pp. 31 - 31, http://dx.doi.org/10.1016/j.bone.2006.01.124

Kavanagh KL; Guo K; Wu X; Knapp S; Ebetino FH; Dunford JE; Rogers MJ; Russell RGG; Oppermann U, 2006, 'Crystal structures and molecular interactions of risedronate and zoledronate with human farnesyl diphosphate synthase', Bone, 38, pp. 53 - 53, http://dx.doi.org/10.1016/j.bone.2005.12.050

Thompson K; Rogers MJ; Coxon FP; Crockett JC, 2006, 'Cytosolic entry of Bisphosphonates into macrophages and osteoclasts requires fluid-phase endocytosis and endosomal acidification', Bone, 38, pp. 47 - 47, http://dx.doi.org/10.1016/j.bone.2005.12.035

Coxon FP; Dunford JE; Rogers MJ, 2006, 'Inhibition of post-translational prenylation causes sustained activation of RAC, Cdc42 and Rho GTPases', Bone, 38, pp. 45 - 45, http://dx.doi.org/10.1016/j.bone.2005.12.031

Dunford JE; Kavanagh K; Oppermann U; Ebetino FH; Russell RGG; Rogers MJ, 2006, 'Investigations into the kinetic mechanism of inhibition of farnesyl diphosphate synthase by nitrogen containing bisphosphonates', Bone, 38, pp. 47 - 48, http://dx.doi.org/10.1016/j.bone.2005.12.037

Ebetino FH; Kashemirov B; McKenna CE; Evdokimov A; Pokross M; Barnett BL; Dunford J; Kavanagh K; Rogers MJ; Lundy MW; Oppermann U; Russell RGG, 2006, 'Molecular modeling comparison of nitrogen-containing bisphosphonates of varying potency co-crystalized in farnesyl diphosphate synthase', Bone, 38, pp. 49 - 50, http://dx.doi.org/10.1016/j.bone.2005.12.042

Garrioch S; Roelofs AJ; Ebetino FH; Rogers MJ, 2006, 'Prevention of breast cancer cell adhesion to bone in vitro by bisphosphonates is mediated by their inhibitory effect on protein prenylation', Bone, 38, pp. 59 - 60, http://dx.doi.org/10.1016/j.bone.2005.12.066

Coxon FP; Thompson K; Ebetino FH; Rogers MJ, 2006, 'Resorbing osteoclasts increase the availability of mineral-bound bisphosphonates to non-resorbing cells', Bone, 38, pp. 45 - 46, http://dx.doi.org/10.1016/j.bone.2005.12.032

Coxon FP; Navea JR; Stewart CA; Al Jaber J; Ebetino FH; McKenna CE; Kashemirov BA; Mallard I; Rogers MJ, 2006, 'Structure-activity relationships of bisphosphonate analogues', Bone, 38, pp. 46 - 46, http://dx.doi.org/10.1016/j.bone.2005.12.033

Coxon FP; Navea JR; Stewart CA; Thompson K; Roelofs A; Ebetino FH; McKenna CE; Kashemirov BA; Bala J; Rogers MJ, 2006, 'Target enzyme specificity, potency and potential lack of side-effects of novel phosphonocarboxylate analogues of bisphosphonates', Bone, 38, pp. 46 - 47, http://dx.doi.org/10.1016/j.bone.2005.12.034

Guenther A; Gordon S; Bakker F; Burger R; Tiemann M; Green JR; Rogers M; Gramatzki M, 2005, 'Zoledronate Exerts Direct Antiproliferative and Apoptotic Effects on Human Myeloma Cells In Vitro and In Vivo.', Blood, 106, pp. 3387 - 3387, http://dx.doi.org/10.1182/blood.v106.11.3387.3387

Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ, 2005, 'Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo', Bone, 37, pp. 349 - 358, http://dx.doi.org/10.1016/j.bone.2005.04.021

Luckman SP; Hughes DE; Coxon FP; Russell GG; Rogers MJ, 2005, 'JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).', Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 20, pp. 1265 - 1274, http://dx.doi.org/10.1359/jbmr.2005.20.7.1265

Rogers MJ, 2004, 'From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates', Calcified Tissue International, 75, pp. 451 - 461, http://dx.doi.org/10.1007/s00223-004-0024-1

Guenther A; Gordon S; Bakker F; Burger R; Green JR; Rogers M; Gramatzki M, 2004, 'Zoledronic Acid Inhibits Protein Prenylation in Plasmacytoma Tumors In Vivo and Enhances Survival in the INA-6 SCID Mouse Model.', Blood, 104, pp. 3360 - 3360, http://dx.doi.org/10.1182/blood.v104.11.3360.3360

Thompson K; Rogers MJ, 2004, 'Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation in Vitro', Journal of Bone and Mineral Research, 19, pp. 278 - 288, http://dx.doi.org/10.1359/JBMR.0301230

Rogers MJ, 2003, 'New insights into the molecular mechanisms of action of bisphosphonates', Current Pharmaceutical Design, 9, pp. 2643 - 2658, http://dx.doi.org/10.2174/1381612033453640

Mburu P; Mustapha M; Varela A; Weil D; El-Amraoui A; Holme RH; Rump A; Hardisty RE; Blanchard S; Coimbra RS; Perfettini I; Parkinson N; Mallon AM; Glenister P; Rogers MJ; Paige AJ; Moir L; Clay J; Rosenthal A; Liu XZ; Blanco G; Steel KP; Petit C; Brown SDM, 2003, 'Defects in whirlin, a PDZ domain molecule involved in stereocilia elongation, cause deafness in the whirler mouse and families with DFNB31', Nature Genetics, 34, pp. 421 - 428, http://dx.doi.org/10.1038/ng1208

Frith JC; Rogers MJ, 2003, 'Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro', Journal of Bone and Mineral Research, 18, pp. 204 - 212, http://dx.doi.org/10.1359/jbmr.2003.18.2.204

Coxon FP; Frith JC; Benford HL; Rogers MJ, 2003, 'Isolation and purification of rabbit osteoclasts.', Methods in molecular medicine, 80, pp. 89 - 99, http://dx.doi.org/10.1385/1-59259-366-6:89

Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JHM, 2003, 'The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity', Journal of Bone and Mineral Research, 18, pp. 88 - 96, http://dx.doi.org/10.1359/jbmr.2003.18.1.88

Coxon FP; Rogers MJ, 2003, 'The role of prenylated small GTP-binding proteins in the regulation of osteoclast function', Calcified Tissue International, 72, pp. 80 - 84, http://dx.doi.org/10.1007/s00223-002-2017-2

Gordon S; Helfrich MH; Sati HIA; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ, 2002, 'Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma', British Journal of Haematology, 119, pp. 475 - 483, http://dx.doi.org/10.1046/j.1365-2141.2002.03824.x

Green JR; Rogers MJ, 2002, 'Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption', Drug Development Research, 55, pp. 210 - 224, http://dx.doi.org/10.1002/ddr.10071

Rogers MJ; Russell RG; Watts NB, 2002, 'Meeting report from what is new in bisphosphonates: Sixth workshop on bisphosphonates', BoneKEy-Osteovision, http://dx.doi.org/10.1138/2002041

Lehenkari PP; Kellinsalmi M; Näpänkangas JP; Ylitalo KV; Mönkkönen J; Rogers MJ; Azhayev A; Kalervo Väänänen H; Hassinen IE, 2002, 'Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite', Molecular Pharmacology, 61, pp. 1255 - 1262, http://dx.doi.org/10.1124/mol.61.5.1255

Thompson K; Dunford JE; Rogers MJ; Ebetino FH, 2002, 'Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase', Biochemical and Biophysical Research Communications, 290, pp. 869 - 873, http://dx.doi.org/10.1006/bbrc.2001.6289

Coxon FP; Helfrich MH; Larijani B; Muzylak M; Dunford JE; Marshall D; McKinnon AD; Nesbitt SA; Horton MA; Seabra MC; Ebetino FH; Rogers MJ, 2001, 'Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages', Journal of Biological Chemistry, 276, pp. 48213 - 48222, http://dx.doi.org/10.1074/jbc.M106473200

Mönkkönen H; Rogers MJ; Makkonen N; Niva S; Auriola S; Mönkkönen J, 2001, 'The cellular uptake and metabolism of clodronate in RAW 264 macrophages', Pharmaceutical Research, 18, pp. 1550 - 1555, http://dx.doi.org/10.1023/A:1013026313647

Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank MA; Phipps RJ; Rogers MJ, 2001, 'Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity', Bone, 29, pp. 336 - 343, http://dx.doi.org/10.1016/S8756-3282(01)00589-0

Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ, 2001, 'The Molecular Mechanism of Action of the Antiresorptive and Antiinflammatory Drug Clodronate: Evidence for the Formation in Vivo of a Metabolite That Inhibits Bone Resorption and Causes Osteoclast and Macrophage Apoptosis', Arthritis and Rheumatism, 44, pp. 2201 - 2210, http://dx.doi.org/10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E

Benford HL; McGowan NWA; Helfrich MH; Nuttall ME; Rogers MJ, 2001, 'Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro', Bone, 28, pp. 465 - 473, http://dx.doi.org/10.1016/S8756-3282(01)00412-4

Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ, 2001, 'Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates', Journal of Pharmacology and Experimental Therapeutics, 296, pp. 235 - 242

Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RGG; Croucher PI, 2000, 'The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma', British Journal of Haematology, 111, pp. 283 - 286, http://dx.doi.org/10.1046/j.1365-2141.2000.02310.x

Mönkkönen H; Moilanen P; Mönkkönen J; Frith JC; Rogers MJ; Auriola S, 2000, 'Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry', Journal of Chromatography B: Biomedical Sciences and Applications, 738, pp. 395 - 403, http://dx.doi.org/10.1016/S0378-4347(99)00559-9

Paige AJW; Kiernan BW; Varela A; Rogers MJC; Hughes D; Steel KP; Brown SDM, 2000, 'A deletion on chromosome 4 cosegregates with the whirler deafness mutation: Exclusion of Orm1 as a candidate', Mammalian Genome, 11, pp. 51 - 57, http://dx.doi.org/10.1007/s003350010010

Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ, 2000, 'Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298', Journal of Bone and Mineral Research, 15, pp. 1467 - 1476, http://dx.doi.org/10.1359/jbmr.2000.15.8.1467

Rogers MJ, 2000, 'Statins: Lower lipids and better bones?', Nature Medicine, 6, pp. 21 - 23, http://dx.doi.org/10.1038/71484

Rogers MJC; Fleming J; Kiernan BW; Mburu P; Varela A; Brown SDM; Steel KP, 1999, 'Genetic mapping of the whirler mutation', Mammalian Genome, 10, pp. 513 - 519, http://dx.doi.org/10.1007/s003359901032

Makkonen N; Salminen A; Rogers MJ; Frith JC; Urtti A; Azhayeva E; Mönkkönen J, 1999, 'Contrasting effects of alendronate and clodronate on RAW 264 macrophages: The role of a bisphosphonate metabolite', European Journal of Pharmaceutical Sciences, 8, pp. 109 - 118, http://dx.doi.org/10.1016/S0928-0987(98)00065-7

Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RGG; Rodan GA; Reszka AA, 1999, 'Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro', Proceedings of the National Academy of Sciences of the United States of America, 96, pp. 133 - 138, http://dx.doi.org/10.1073/pnas.96.1.133

Back to profile page